Short answer
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $99M (up 65.7% year over year) with net income of −$47M.
Q2 2026 key financials · XBRL
- Revenue
- $99M
- +65.7% YoY · +39.0% QoQ
- Net income
- −$47M
- +57.6% YoY · +40.1% QoQ
- Operating margin
- -52.3%
- EPS (diluted)
- −$0.10
- +69.7% YoY · +47.4% QoQ
Source: XBRL data from the IOVANCE BIOTHERAPEUTICS, INC. (IOVA) Q2 2026 10-Q on SEC EDGAR. USD.
IOVANCE BIOTHERAPEUTICS, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $99.3M, up 66% YoY from $60.0M
- Amtagvi revenue $90.7M, up 68% YoY; Proleukin $8.6M, up 46%
- Cost of sales $43.6M, down 11% YoY; total costs and expenses $151.2M, down 13%
- Near-term expansion: Australia authorization, UK expedited review with potential approval later in 2026, EU resubmission planned in 2026 or 2027
Risk Factors
- Newly added tax risk: OBBBA changes and ACA premium-credit expiration expected to reduce Marketplace coverage by approximately 24 million people
- Most materially updated financial risk: Cash resources $303.7 million at June 30, 2026, insufficient for planned manufacturing expansion
- Regulatory risk: FDA or foreign authorities may impose post-marketing requirements requiring substantial time, effort, and money
- Operational risk: Workforce reduction of approximately 19% may disrupt operations and delay strategic initiatives
- Financial risk: $1.7 billion in federal NOL carryforwards faces Section 382 limitations after future ownership changes
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other IOVANCE BIOTHERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.